PAS
KLRS

Point72 Asia (Singapore)’s Kalaris Therapeutics KLRS Stock Holding History

Point72 Asia (Singapore)’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,169
Closed -$11.3K – 1265
2024
Q4 		$11.3K Sell
1,169
-147
-11% -$2.22K ﹤0.01% 729
2024
Q3 		$24.5K Sell
1,316
-2,000
-60% -$35K ﹤0.01% 797
2024
Q2 		$55.2K Buy
+3,316
New +$58.5K 0.01% 628

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asia (Singapore)'s KLRS Position: Q1 2025 in Review

Point72 Asia (Singapore) sold out of Kalaris Therapeutics (KLRS) in Q1 2025, closing a stake of 1,169 shares — an estimated $11.3K sold.

Point72 Asia (Singapore) first reported a position in KLRS in Q2 2024 and held it in 3 quarters. The position peaked at $55.2K in Q2 2024. 32 funds tracked by Wall St. Rank hold KLRS as of Q1 2025.

  • Point72 Asia (Singapore) reported no remaining Kalaris Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 1,169 Kalaris Therapeutics shares in Q1 2025, an estimated $11.3K.
  • Point72 Asia (Singapore) first reported a position in Kalaris Therapeutics in Q2 2024 and held it in 3 quarters.
  • Point72 Asia (Singapore)'s Kalaris Therapeutics position peaked at $55.2K in Q2 2024.
  • 32 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q1 2025, filed 15 May 2025.